Skip to content
Trial Eligibility
Menu

Crohn's Disease Clinical Trials Recruiting in the US

101 studies for Crohn's Disease are recruiting at 1,214 US sites, according to ClinicalTrials.gov data processed .

Crohn's disease is a type of inflammatory bowel disease that causes chronic inflammation in parts of the digestive tract.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Top Crohn's Disease studies by number of US sites

Showing 30 studies, most US recruiting sites first.
  1. An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

    NCT07184931

    • Phase 3
    • Ages 16 to 80 years
    • Sex: All
    Recruiting sites
    125 US recruiting sites
  2. A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

    NCT06819878

    • Phase 3
    • Ages 16 to 80 years
    • Sex: All
    Recruiting sites
    93 US recruiting sites
  3. A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

    NCT06581328

    • Phase 4
    • Ages 18 to 80 years
    • Sex: All
    Recruiting sites
    78 US recruiting sites
  4. A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

    NCT06430801

    • Phase 3
    • Ages 16 to 80 years
    • Sex: All
    Recruiting sites
    71 US recruiting sites
  5. Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

    NCT07697456

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    60 US recruiting sites
  6. A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

    NCT06819891

    • Phase 3
    • Ages 16 to 80 years
    • Sex: All
    Recruiting sites
    59 US recruiting sites
  7. Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

    NCT06548542

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    54 US recruiting sites
  8. A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

    NCT07196722

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    54 US recruiting sites
  9. A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

    NCT07113522

    • Phase 2
    • Ages 18 to 80 years
    • Sex: All
    Recruiting sites
    46 US recruiting sites
  10. A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

    NCT06045754

    • Phase 4
    • Ages 18 to 70 years
    • Sex: All
    Recruiting sites
    41 US recruiting sites
  11. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    NCT03816345

    • Phase 1
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    40 US recruiting sites
  12. A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

    NCT07499232

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    36 US recruiting sites
  13. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

    NCT06937099

    • Phase 3
    • Ages 18 to 70 years
    • Sex: All
    Recruiting sites
    35 US recruiting sites
  14. A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

    NCT07184944

    • Phase 3
    • Ages 16 to 80 years
    • Sex: All
    Recruiting sites
    34 US recruiting sites
  15. A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

    NCT06233461

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    24 US recruiting sites
  16. Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

    NCT06456593

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    24 US recruiting sites
  17. A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

    NCT06226883

    • Phase 2
    • Ages 18 to 85 years
    • Sex: All
    Recruiting sites
    23 US recruiting sites
  18. A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

    NCT07577843

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    22 US recruiting sites
  19. Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

    NCT05781152

    • Phase 4
    • Ages 6 to 17 years
    • Sex: All
    Recruiting sites
    21 US recruiting sites
  20. Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

    NCT05230173

    • Interventional
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    19 US recruiting sites
  21. A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

    NCT06958536

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    19 US recruiting sites
  22. Treatment of Moderate to Severe Refractory Crohn's Disease

    NCT06721962

    • Phase 1/2
    • Ages 18 to 65 years
    • Sex: All
    Recruiting sites
    13 US recruiting sites
  23. Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

    NCT06332534

    • Phase 3
    • Ages 2 to 17 years
    • Sex: All
    Recruiting sites
    12 US recruiting sites
  24. Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

    NCT06651281

    • Phase 3
    • Ages Any age
    • Sex: All
    Recruiting sites
    12 US recruiting sites
  25. A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

    NCT07483073

    • Phase 2
    • Ages 18 to 80 years
    • Sex: All
    Recruiting sites
    12 US recruiting sites
  26. A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

    NCT05509777

    • Phase 3
    • Ages 2 to 17 years
    • Sex: All
    Recruiting sites
    11 US recruiting sites
  27. Precise Infliximab Exposure and Pharmacodynamic Control

    NCT05660746

    • Phase 2/3
    • Ages 6 to 22 years
    • Sex: All
    Recruiting sites
    11 US recruiting sites
  28. Zymfentra (Infliximab-dyyb) REal World Cohort STudy

    NCT07237516

    • Observational
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    11 US recruiting sites
  29. A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

    NCT05995353

    • Phase 3
    • Ages 2 to 17 years
    • Sex: All
    Recruiting sites
    10 US recruiting sites
  30. A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

    NCT07483099

    • Phase 2
    • Ages 18 to 80 years
    • Sex: All
    Recruiting sites
    10 US recruiting sites

By city

Crohn's Disease clinical trials by city

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Crohn's Disease clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.